09/19/23 8:00 AMNasdaq : SCPH low floatscPharmaceuticals Announces Positive Feedback from Two FDA Meetings on Key Long-Term Growth InitiativesCompany advancing plans to expand the FUROSCIX franchise to include an 80mg/1ml auto-injector as an additional delivery system designed to provide greater flexibility to heart failure patients Agency confirms no additional clinical data required to pursue label expansion of FUROSCIX into chronicRHEA-AIneutral
09/05/23 8:00 AMNasdaq : SCPH conferenceslow floatscPharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment ConferencescPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, todayRHEA-AIneutral
08/10/23 4:01 PMNasdaq : SCPH earningslow floatscPharmaceuticals Inc. Reports Second Quarter 2023 Financial Results and Provides Business UpdateRHEA-AIneutral
08/03/23 8:00 AMNasdaq : SCPH earningslow floatscPharmaceuticals to Announce Second Quarter 2023 Financial Results on Thursday, August 10, 2023scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patientRHEA-AIneutral
08/01/23 8:00 AMNasdaq : SCPH low floatscPharmaceuticals Announces Positive Type C Meeting Feedback from FDA on Potential Heart Failure Class IV Indication ExpansionscPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have theRHEA-AIneutral
07/19/23 8:00 AMNasdaq : SCPH low floatscPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)scPharmaceuticals Inc. (Nasdaq: SCPH) (“scPharmaceuticals” or the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcareRHEA-AIpositive
06/23/23 8:00 AMNasdaq : SCPH low floatscPharmaceuticals Inc. Announces Addition to Russell 2000® and Russell 3000® IndexesscPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, todayRHEA-AIneutral
05/31/23 8:00 AMNasdaq : SCPH conferenceslow floatscPharmaceuticals to Present at the Jefferies Healthcare ConferencescPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, todayRHEA-AIneutral
05/10/23 4:01 PMNasdaq : SCPH earningslow floatscPharmaceuticals Inc. Reports First Quarter 2023 Financial Results and Provides Business UpdateAnnounced launch and commercial availability of FUROSCIX® on February 20 th Generated net FUROSCIX revenue of $2.1 million Ended Q1 2023 with cash, cash equivalents and short-term investments o f $116.1 million Company to host investor conference call and webcast today, Wednesday, May 10, at 4:30pmRHEA-AIneutral
05/02/23 8:00 AMNasdaq : SCPH earningslow floatscPharmaceuticals to Announce First Quarter 2023 Financial Results on Wednesday, May 10, 2023scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patientRHEA-AIneutral